BiotechTubeBiotechTube
Home/Investors/Public shareholders via Shenzhen Stock Exchange

Public shareholders via Shenzhen Stock Exchange

Biotech Investor · 2 portfolio companies

Portfolio
2
Combined Value
$113.0B
Focus Areas
8
Top Stage
Commercial

Investment Focus

CardiovascularRespiratoryMetabolic DiseasesGeneric DrugsOncologyCentral Nervous SystemMetabolic DisordersImmunology

Portfolio Companies

CompanyValuation
Shenzhen Salubris Pharmaceuticals$64.8B
Pharmaron Beijing$48.2B